Peripheral endothelial dysfunction is a novel risk factor for systolic dysfunction and heart failure progression.

ABSTRACT:

Background

ACC/AHA guidelines recognize the progressive nature of heart failure (HF). Patients with risk factors (Stage A) are at risk for developing asymptomatic cardiac dysfunction (Stage B), which may then lead to symptomatic HF (Stage C). As such, therapies targeting abnormalities in stages A and B may protect against development of symptomatic HF. peripheral endothelial dysfunction (PED) is an independent predictor of adverse outcomes in patients with stage C HF. The aim of the current study was to evaluate whether PED might be associated with Stage B HF, where therapeutic interventions to prevent progression might be more efficacious.

Methods

We performed a retrospective cross-sectional analysis of patients who were referred for routine cardiovascular evaluation that i

SUBMITTER: Taher R 

PROVIDER: S-EPMC7385446 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature